Skip to content

    Akums Drugs Q1 FY27 earnings call

    AKUMS
    Healthcare·10 Aug 2026
    Management Summary

    Akums Drugs & Pharmaceuticals reported a strong Q1 FY27, with double-digit revenue and profit growth, primarily driven by its CDMO segment. Margins expanded significantly due to volume growth and improved API prices. The company also completed the acquisition of Oriflame India's manufacturing business to expand into skin care and wellness products. While certain marketing segments faced muted performance and the API business remained loss-making, management expressed confidence in their turnaround and growth strategies, supported by a robust cash-rich, debt-free balance sheet.

    Highlights

    5

    • Operating Revenue grew 13.9% YoY to ₹1,167 crores, indicating strong top-line performance.

    • Operating EBITDA increased 35.4% YoY to ₹175 crores, with margins expanding 238 bps to 15%, driven by CDMO and API price improvements.

    • PAT surged 56.1% YoY to ₹101 crores, reflecting strong operational leverage and improved profitability.

    • CDMO segment delivered robust growth of 18.6% YoY, reaching ₹964 crores, supported by volume growth and better API prices.

    • The company maintains a healthy balance sheet with a cash surplus of ₹1,616 crores and no debt, providing flexibility for future growth.

    Concerns

    4

    • Domestic branded formulation (Akumentis) EBITDA declined 25.4% YoY to ₹12 crores, impacted by increased employee strength (200 new field force personnel).

    • API segment remained EBITDA negative at minus ₹4 crores, despite lower losses compared to previous quarters.

    • International branded formulation revenue declined 1.5% YoY to ₹35 crores, experiencing a muted quarter.

    • Trade generics revenue decreased 9.5% YoY to ₹21 crores.

    Key financials

    Single quarter

    04 metrics
    1. 01Operating Revenue₹1,167 Cr+13.9%YoY
    2. 02Operating EBITDA₹175 Cr+35.4%YoY
    3. 03Operating EBITDA Margin15%
    4. 04PAT₹101 Cr+56.1%YoY

    Segment breakdown

    • CDMO₹964 Cr82.6%
    • Domestic Branded Formulation₹115 Cr9.9%
    • International Branded Formulation₹35 Cr3.0%
    • API₹32 Cr2.7%
    • Trade Generics₹21 Cr1.8%
    Donut· Share of Revenue

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Debt

    Gross ₹0 crores · Net ₹-1,616 crores

    M&A

    Oriflame India's manufacturing business

    acquisition · closed

    Liquidity

    Cash ₹1,616 crores

    98% of the cash surplus is parked in fixed deposits with nationalized banks.

    Guidance & targets

    6
    CategoryTargetPriority
    Volume
    Overall Volume Growth
    double digits
    		High
    Margin
    Overall EBITDA Margins
    14% to 15%
    		High
    Profitability
    API Segment Profitability
    EBITDA positive
    		High
    Revenue
    Zambia Sales
    INR240 crores
    		High
    Business Launch
    European Business Kickoff
    kickstart
    		High
    Capacity
    New Baddi Facility Go-Live
    go live
    		High

    What to watch in Q2 FY27

    5

    API Segment Profitability

    by FY27 / next fiscal
    CurrentEBITDA negative (minus ₹4 crores)
    TargetMonthly EBITDA positive by Feb/Mar FY27, positive contribution next fiscal

    Why it matters

    Achievement of API profitability is key to overall margin improvement and validates management's commitment to the business.

    Absolutely right, Abdul. So the whole target is on a monthly level, at least by the end of February, March, we should be monthly EBITDA positive in this business. And then next year, we should start positively contributing to the profit from this segment.

    Risks & concerns

    4
    RiskSeverity

    Muted performance in marketing segments (domestic and exports)

    Domestic and export marketing segments saw muted quarterly performances, though initiatives are underway for recovery. — Management acknowledged

    medium

    EBITDA impact from increased employee strength in Akumentis

    Margins for domestic branded formulations were impacted by the addition of 200 field force personnel, leading to an EBITDA drain in Q1. — Management acknowledged

    medium

    API business remaining EBITDA negative

    The API segment recorded an EBITDA loss of ₹4 crores, though losses were lower than previous quarters, with a target for profitability by FY27. — Management acknowledged

    medium

    API price volatility

    API prices are volatile, though currently showing an upward trend, impacting gross margins. — Management acknowledged

    medium

    Q&A highlights

    5

    “So the management is fully confident, right? So this is a business we have been investing for over 3, 4 years now. The fruits of which are very visible as we speak, right? So the quarterly losses have been gradually coming down. So as far as we speak as of now, we are fully into this business.”

    An analyst challenged management's strategy on continuing the loss-making API business, to which management reiterated commitment and explained the path to profitability.

    asked by Andrey

    2 min read6 chapters

    Detailed Narrative

    01

    Robust Q1 FY27 Financial Performance

    Akums Drugs & Pharmaceuticals reported a strong start to FY27, with operating revenue growing 13.9% year-on-year to ₹1,167 crores. Operating EBITDA saw a significant increase of 35.4% year-on-year, reaching ₹175 crores, leading to a 238 basis points expansion in operating EBITDA margin to 15%. Net profit after tax (PAT) surged 56.1% year-on-year to ₹101 crores, demonstrating strong operational leverage and improved profitability across the business.

    02

    CDMO Segment as Key Growth Driver

    The Contract Development and Manufacturing Organization (CDMO) segment continued to be the primary growth engine, delivering a healthy top-line growth of over 18.6% year-on-year, with revenue reaching ₹964 crores. This growth was attributed to double-digit volume expansion and an improvement in API prices. The CDMO segment's EBITDA also increased by 36.8% year-on-year to ₹163 crores, with margins further aided by improved capacity utilization.

    03

    Strategic Expansion into Skin Care and Wellness

    In a strategic move, Akums announced the acquisition of Oriflame India's manufacturing business on July 23, 2026. This transaction includes two manufacturing facilities in Roorkee and Noida, along with a leased warehouse. The acquisition is aligned with the company's strategy to expand its manufacturing footprint in skin care cosmetics and wellness products, tapping into niche formulations to enhance its market position and augment margins.

    04

    Mixed Performance in Marketing Segments

    While the CDMO segment thrived, the domestic and international branded formulation businesses experienced muted quarterly performances. Domestic branded formulation (Akumentis) revenue grew 7.3% to ₹115 crores, but its EBITDA declined 25.4% to ₹12 crores due to an increase in employee strength (200 new field force personnel). The international branded formulation business saw a 1.5% decline in revenue to ₹35 crores. Management expects these segments to return to a growth path in the coming quarters⏳ through various initiatives.

    05

    API Business Turnaround Efforts

    The API segment continued to be EBITDA negative, reporting a loss of ₹4 crores, though this was an improvement from previous quarters. Management remains committed to the API business, with a focus on increasing non-cepha products to improve margins. The target is to achieve monthly EBITDA positive status by February-March FY27 and for the segment to start positively contributing to profit from the next financial year.

    06

    Strong Balance Sheet and Capital Allocation

    Akums maintains a very healthy balance sheet with a significant cash surplus of ₹1,616 crores and no debt. Approximately 98% of this cash is securely parked in fixed deposits with nationalized banks. The company's net worth stands at over ₹3,400 crores. Management indicated a focus on value-accretive mergers and acquisitions and capacity expansion, such as the new facility in Baddi expected to go live by the end of the current financial year, to drive future growth.

    This is an AI-generated summary of a publicly available earnings call transcript.